A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...

Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.

FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Many patients with metastatic castration-resistant prostate cancer are not receiving bone-modifying agents, despite guideline endorsement.

The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway ...

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered—chronological age. The study, published ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...

Scott Adams, creator of the comic strip “Dilbert,” has died after being diagnosed with metastatic prostate cancer. He was 68.

For men with genitourinary malignancies, such as prostate cancer, examining the external genital area is essential. While this may seem routine, it remains a crucial recommendation, as illustrated by ...